Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brinsupri
Pharma
Insmed terminates development of Brinsupri in another indication
Insmed has terminated development of Brinsupri for hidradenitis suppurativa after it failed to top placebo in a phase 2b trial.
Kevin Dunleavy
Apr 8, 2026 7:57am
Insmed plots key expansion for Arikayce on new data
Mar 23, 2026 11:21am
Insmed forecasts sales of Brinsupri will reach $1B in 2026
Feb 19, 2026 11:45am
Upside for Insmed after Brinsupri’s first-in-class sales beat
Jan 9, 2026 10:40am
Insmed's Brinsupri comes up short in rhinosinusitis trial
Dec 18, 2025 11:27am
